Search clinical trials for: Lu AF11167

Total 286 results

H. Lundbeck A/S

Completed

Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167

Schizophrenia

United Kingdom
H. Lundbeck A/S

Terminated

Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms

Schizophrenia

Bulgaria, Estonia, Hungary, Latvia, Ukraine, Germany, Poland
H. Lundbeck A/S

Terminated

Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia

Schizophrenia

Bulgaria, Czechia, Estonia, Germany, Hungary, Latvia, Poland, Ukraine
H. Lundbeck A/S

Completed

A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

Schizophrenia

United States
H. Lundbeck A/S

Terminated

Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease

Alzheimer Disease

Austria, Finland, Sweden
H. Lundbeck A/S

Completed

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

Parkinson Disease

United States
H. Lundbeck A/S

Completed

Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men

Healthy

Netherlands
H. Lundbeck A/S

Completed

Bioequivalence Study of Lu AF35700

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State

Healthy

United Kingdom
OHSU Knight Cancer Institute
Novartis; Oregon Health and Science University

Not yet recruiting

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Metastatic Adrenal Gland Pheochromocytoma | Stage III Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IV Thyroid Gland Medullary Carcinoma AJCC v8 | Locally Advanced Adrenal Gland Pheochromocytoma | Locally Advanced Paraganglioma | Metastatic Paraganglioma | Metastatic Parathyroid Gland Carcinoma and other conditions

United States
H. Lundbeck A/S

Completed

Absolute Bioavailability of Lu AE58054 in Healthy Subjects

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine

Healthy

United Kingdom
Chung Shan Medical University

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren's Syndrome.

Sjögren's Syndrome

Taiwan
H. Lundbeck A/S

Completed

A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

Migraine

United States
H. Lundbeck A/S

Terminated

A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy

Focal Epilepsy

United States
H. Lundbeck A/S

Terminated

Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants

Healthy Volunteers

Japan
H. Lundbeck A/S

Terminated

A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia

Fibromyalgia

United States
H. Lundbeck A/S

Recruiting

Lu AF28996 in Participants With Parkinson's Disease (PD)

Parkinson Disease

United States, Netherlands
H. Lundbeck A/S

Completed

Binding and Effects of Lu AG06466 in the Brain of Healthy Men

Healthy Participants

United States
H. Lundbeck A/S

Completed

A Study in Healthy Men to Investigate Uptake and Distribution of Lu AF88434 in the Brain

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Study to Evaluate the Effect of a Known and Marketed Product, Itraconazole (Mycosis Treatment) on Lu AF11167 Entering the Body and Subsequently Elimination. The Study is a Drug-drug Interaction Study in Healthy Volunteers.

Healthy

United Kingdom
Sinotau Pharmaceutical Group

Not yet recruiting

Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer

Prostate Cancer

China
H. Lundbeck A/S

Completed

Single Dose of Lu AF28996 to Healthy Young Men

Healthy

Netherlands
H. Lundbeck A/S

Completed

A Trial Investigating Lu AF28996 in Adult Japanese Participants With Parkinson's Disease (PD)

Parkinson Disease

Japan
H. Lundbeck A/S

Completed

Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia (Debut)

Schizophrenia

Estonia, Mexico, Russian Federation, Serbia, Ukraine, United States, Bulgaria, Canada, Czechia, Poland, Slovakia, Spain, Romania
H. Lundbeck A/S

Terminated

Pharmacokinetics of Lu AF35700 in Subjects With Renal Impairment

Renal Failure

Germany
Instituto Nacional de Cancer, Brazil

Unknown

Radiolabeled Molecules for Medullary Thyroid Cancer

Medullary Thyroid Cancer

Brazil
Shanghai Tongji Hospital, Tongji University School...

Approved for marketing

Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.

HDFN
H. Lundbeck A/S

Terminated

Safety and Tolerability of Lu AF95245 in Healthy Young Men

Healthy

Netherlands
H. Lundbeck A/S

Recruiting

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments (PROCEED)

Migraine

United States
H. Lundbeck A/S

Completed

A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

Migraine

United States, Czechia, Denmark, Georgia, Poland, Slovakia
H. Lundbeck A/S

Active, not recruiting

A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis

Multiple Sclerosis

United States, Germany
H. Lundbeck A/S

Completed

A Trial to Learn More About Repeated Monthly Injections of Lu AG09222 in Participants With Allergies to Grass Pollen

Allergic Rhinitis

United Kingdom
H. Lundbeck A/S

Completed

A Brain Imaging PET Study of [11C]-Lu AF88370 in Healthy Adult Male Participants

Healthy Participants

United Kingdom
H. Lundbeck A/S

Completed

A Brain Imaging PET Study of [11C]-Lu AF90103 in Healthy Adult Male Participants

Healthy Young Men

Sweden
H. Lundbeck A/S

Terminated

Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease

Alzheimer's Disease

United States
H. Lundbeck A/S

Completed

Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)

PTSD

United States
H. Lundbeck A/S

Completed

A Study Investigating Lu AG06466 in Healthy Men

Healthy Volunteers

United Kingdom
H. Lundbeck A/S

Terminated

Safety and Tolerability of Lu AG06479 in Healthy Young Men

Healthy

United States
AHS Cancer Control Alberta

Recruiting

A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

Carcinoma, Neuroendocrine

Canada
University Health Network, Toronto
Cancer Care Ontario; Ozmosis Research Inc.; Canadian Molecular Imaging Probe...

Active, not recruiting

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

Neuroendocrine Tumors

Canada
H. Lundbeck A/S

Completed

D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound

Healthy Men

United Kingdom
Spago Nanomedical AB

Recruiting

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer (Tumorad)

Solid Tumor | Metastatic Cancer | Refractory Cancer | Locally Advanced Solid Tumor | Unresectable Solid Tumor | Recurrent Solid Tumor

Australia
H. Lundbeck A/S

Completed

Binding of Lu AG06466 in the Brain in Healthy Men

Healthy

Belgium
POINT Biopharma

Active, not recruiting

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Soft Tissue Sarcoma | Colorectal Cancer | Esophageal Cancer | Cholangiocarcinoma | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Melanoma (Skin)

United States, Canada
Nantes University Hospital

Not yet recruiting

Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia. (PENTILULA)

Acute Leukemia

France
Bivision Pharmaceuticals, Inc.

Recruiting

Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

Prostate Cancer

China

3

Subscribe